Status:
UNKNOWN
Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn
Lead Sponsor:
Bnai Zion Medical Center
Conditions:
Transient Tachypnea of the Newborn
Eligibility:
All Genders
4-6 years
Phase:
PHASE2
Brief Summary
Transient Tachypnea of the Newborn (TTN) is a common respiratory disorder affecting late preterm and term babies caused by lung edema resulting from delayed absorption of fetal alveolar lung fluid. T...
Detailed Description
The primary outcome measure will be the assessment of respiratory distress reflected by TTN clinical score in neonates presenting with TTN and treated with inhaled corticosteroids compared to placebo.
Eligibility Criteria
Inclusion
- Late preterm and term infants (post-menstrual age ≥ 34 weeks) delivered by cesarean section or vaginal delivery
- Diagnosis of TTN
- Parents signed informed consent
Exclusion
- Meconium aspiration syndrome
- Respiratory distress syndrome
- Congenital heart disease
- Non respiratory disorders causing tachypnea
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT01858129
Start Date
March 1 2012
Last Update
January 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bnai Zion Medical Center
Haifa, Israel